医学
鼻咽癌
接种疫苗
临床试验
内科学
免疫系统
癌症
肿瘤科
干细胞
免疫学
胃肠病学
鼻咽癌
放射治疗
生物
遗传学
作者
Mao Lin,Yuanying Yuan,Jongyuan Xu,Xiaoling Cai,Shupeng Liu,Lizhi Niu,Jibing Chen,Qiao Li,Kecheng Xu
标识
DOI:10.1016/j.imlet.2015.03.005
摘要
In this trial, nasopharyngeal cancer stem cells (CSCs) were separated and cultured to produce a vaccine; its safety and efficacy were prospectively evaluated in low-, medium-, and high-dose groups. Between April and September 2014, we enrolled 90 patients who met the enrolment criteria, and assigned them to three groups (n=30). Throughout the trial, injection site reaction was the most common reaction (81%), and fever was least common (31%); however, there was no difference among the three groups. When the immune responses pre- and post-vaccination were compared, we found that the CSC-specific and -nonspecific response in the medium- and high-dose groups were both significantly enhanced. This study is the first clinical trial of a nasopharyngeal CSC vaccine and preliminarily proves its safety and efficacy.
科研通智能强力驱动
Strongly Powered by AbleSci AI